Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR L858R”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Testing effectiveness (Phase 2)Looking for participantsNCT07505173
What this trial is testing

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Who this might be right for
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital 74
Testing effectiveness (Phase 2)Ended earlyNCT02349633
What this trial is testing

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 65
Large-scale testing (Phase 3)Active Not RecruitingNCT02511106
What this trial is testing

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Who this might be right for
Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca 682
Large-scale testing (Phase 3)Study completedNCT03653546
What this trial is testing

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationBrain Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 492
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)Study completedNCT05263947
What this trial is testing

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Who this might be right for
Carcinoma, Non-Small-Cell LungBevacizumabTyrosine Kinase Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital 35
Testing effectiveness (Phase 2)Looking for participantsNCT07206498
What this trial is testing

Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Wayshine Biopharm, Inc. 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07709585
What this trial is testing

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Who this might be right for
Advanced Non-small Cell Lung Cancer (NSCLC)EGFR Exon 19 Deletion MutationEGFR Exon 21 Mutation+1 more
Guangzhou University of Traditional Chinese Medicine 124
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Testing effectiveness (Phase 2)Looking for participantsNCT05271916
What this trial is testing

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 140
Early research (Phase 1)Looking for participantsNCT06955988
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 120
Not applicableActive Not RecruitingNCT03969823
What this trial is testing

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Seoul National University Hospital 148
Testing effectiveness (Phase 2)Ended earlyNCT04908956
What this trial is testing

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
ETOP IBCSG Partners Foundation 6
Testing effectiveness (Phase 2)Looking for participantsNCT07624487
What this trial is testing

Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma Metastatic
Taipei Medical University Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Testing effectiveness (Phase 2)Study completedNCT01933347
What this trial is testing

Third-line Treatment of Gefitinib in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT06827145
What this trial is testing

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
National Cancer Center, China 30
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Testing effectiveness (Phase 2)UnknownNCT04988607
What this trial is testing

Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 90
Early research (Phase 1)Not Yet RecruitingNCT07461727
What this trial is testing

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

Who this might be right for
Non-Small Cell Lung CancerMetastatic Non-small Cell Lung CancerLiver Metastases+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Next Page